Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Intensity in Treatment-Resistant Depression (Pilot fMRI Study)
2013-003196-35Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in major depressive disorder (MDD), sponsored by Imperial College London. Primary endpoint: Subjective intensity of psilocybin effects. Started Jul 2015; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2013-003196-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003196-35.